{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:53:48Z","timestamp":1781654028400,"version":"3.54.5"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pituitary neuroendocrine tumors (PitNETs) represent a heterogeneous group of intracranial neoplasms arising from the anterior pituitary gland. While most tumors are benign, certain subsets can display aggressive behavior marked by invasiveness, treatment resistance, and familial clustering. The current World Health Organization (WHO) classification emphasizes the role of lineage-specific transcription factors in better identifying cell types. However, this methodology is not sufficient to ensure fully accurate prediction of tumor behavior; therefore, new, more in-depth methods are required to improve diagnostic reliability and treatment decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review was carried out to evaluate the literature on PitNET classification schemas and their molecular signatures. Attention was placed on classification research and developments that impact current clinical management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Analysis<\/jats:title>\n                    <jats:p>Evidence indicates improvement in the molecular classification of PitNETs, not just from lineage-specific transcription factors, but also from advances in genomic, transcriptomic, and epigenetic profiling. These newer techniques have revealed that PitNETs are driven by a complex interplay of alterations, including somatic mutations, germline predisposition genes, copy number variations, and poorly regulated signaling pathways. Each of these general findings plays a role in influencing tumor behavior, controlling lineage differentiation, and determining response to therapy. These findings indicate the need for integrating molecular characteristics with clinical data to improve risk stratification and guide personalized treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinical data combined with molecular classification systems is redefining our understanding of PitNET behavior and improving clinical decision-making by increasing our diagnostic accuracy and advancing our knowledge of individualized patient tumor biology. Continued research and development of comprehensive predictive approaches are necessary to achieve reliable outcome prediction and improve therapeutic decision-making for all patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05447-0","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:34:40Z","timestamp":1770237280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular biology of pituitary neuroendocrine tumors"],"prefix":"10.1007","volume":"176","author":[{"given":"Reilly L.","family":"Kidwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Trippett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish K.","family":"Aghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"5447_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1530\/Joe-12-0229","volume":"215","author":"DC de Moraes","year":"2012","unstructured":"de Moraes DC, Vaisman M, Conceicao FL, Ortiga-Carvalho TM (2012) Pituitary development: a complex, Temporal regulated process dependent on specific transcriptional factors. J Endocrinol 215:239\u2013245. https:\/\/doi.org\/10.1530\/Joe-12-0229","journal-title":"J Endocrinol"},{"key":"5447_CR2","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1210\/me.2005-0052","volume":"19","author":"MA Charles","year":"2005","unstructured":"Charles MA, Suh H, Hjalt TA, Drouin J, Camper SA, Gage PJ (2005) PITX genes are required for cell survival and Lhx3 activation. Mol Endocrinol 19:1893\u20131903. https:\/\/doi.org\/10.1210\/me.2005-0052","journal-title":"Mol Endocrinol"},{"key":"5447_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev.pathol.4.110807.092259","volume":"4","author":"SL Asa","year":"2009","unstructured":"Asa SL, Ezzat S (2009) The pathogenesis of pituitary tumors. Annu Rev Pathol 4:97\u2013126. https:\/\/doi.org\/10.1146\/annurev.pathol.4.110807.092259","journal-title":"Annu Rev Pathol"},{"key":"5447_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1242\/dev.128.3.377","volume":"128","author":"M Treier","year":"2001","unstructured":"Treier M, O\u2019Connell S, Gleiberman A, Price J, Szeto DP, Burgess R, Chuang PT, McMahon AP, Rosenfeld MG (2001) Hedgehog signaling is required for pituitary gland development. Development 128:377\u2013386. https:\/\/doi.org\/10.1242\/dev.128.3.377","journal-title":"Development"},{"key":"5447_CR5","doi-asserted-by":"publisher","unstructured":"Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C (2020) How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020. Cancers (Basel) 12. https:\/\/doi.org\/10.3390\/cancers12020514","DOI":"10.3390\/cancers12020514"},{"key":"5447_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol 33:6\u201326. https:\/\/doi.org\/10.1007\/s12022-022-09703-7","journal-title":"Endocr Pathol"},{"key":"5447_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","volume":"28","author":"O Mete","year":"2017","unstructured":"Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28:228\u2013243. https:\/\/doi.org\/10.1007\/s12022-017-9498-z","journal-title":"Endocr Pathol"},{"key":"5447_CR8","doi-asserted-by":"publisher","unstructured":"Klimstra DS, Beltran H, Lilenbaum R, Bergsland E (2015) The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book 92\u2013103. https:\/\/doi.org\/10.14694\/EdBook_AM.2015.35.92","DOI":"10.14694\/EdBook_AM.2015.35.92"},{"key":"5447_CR9","doi-asserted-by":"publisher","unstructured":"(2025) Corrigendum to: CBTRUS statistical report: Pediatric Brain Tumor Foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2017\u20132021. Neuro Oncol https:\/\/doi.org\/10.1093\/neuonc\/noaf238","DOI":"10.1093\/neuonc\/noaf238"},{"key":"5447_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72:377\u2013382. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03667.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"5447_CR11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1530\/EJE-15-0189","volume":"173","author":"TT Agustsson","year":"2015","unstructured":"Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV, Carroll PV, Korbonits M, Benediktsson R (2015) The epidemiology of pituitary adenomas in Iceland, 1955\u20132012: a nationwide population-based study. Eur J Endocrinol 173:655\u2013664. https:\/\/doi.org\/10.1530\/EJE-15-0189","journal-title":"Eur J Endocrinol"},{"key":"5447_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1530\/EJE-14-0144","volume":"171","author":"A Tjornstrand","year":"2014","unstructured":"Tjornstrand A, Gunnarsson K, Evert M, Holmberg E, Ragnarsson O, Rosen T, Filipsson Nystrom H (2014) The incidence rate of pituitary adenomas in Western Sweden for the period 2001\u20132011. Eur J Endocrinol 171:519\u2013526. https:\/\/doi.org\/10.1530\/EJE-14-0144","journal-title":"Eur J Endocrinol"},{"key":"5447_CR13","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/s41379-018-0016-8","volume":"31","author":"O Mete","year":"2018","unstructured":"Mete O, Cintosun A, Pressman I, Asa SL (2018) Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol 31:900\u2013909. https:\/\/doi.org\/10.1038\/s41379-018-0016-8","journal-title":"Mod Pathol"},{"key":"5447_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1365-2265.1994.tb02557.x","volume":"41","author":"T Mindermann","year":"1994","unstructured":"Mindermann T, Wilson CB (1994) Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf) 41:359\u2013364. https:\/\/doi.org\/10.1111\/j.1365-2265.1994.tb02557.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"5447_CR15","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1111\/cns.14315","volume":"29","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Zhang A, Fang C, Yuan L, Shao A, Xu Y, Zhou D (2023) Oxidative stress in pituitary neuroendocrine tumors: affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy. CNS Neurosci Ther 29:2744\u20132759. https:\/\/doi.org\/10.1111\/cns.14315","journal-title":"CNS Neurosci Ther"},{"key":"5447_CR16","doi-asserted-by":"publisher","unstructured":"Neou M, Villa C, Armignacco R, Jouinot A, Raffin-Sanson ML, Septier A, Letourneur F, Diry S, Diedisheim M, Izac B, Gaspar C, Perlemoine K, Verjus V, Bernier M, Boulin A, Emile JF, Bertagna X, Jaffrezic F, Laloe D, Baussart B, Bertherat J, Gaillard S, Assie G (2020) Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell 37:123\u2013134.e125. https:\/\/doi.org\/10.1016\/j.ccell.2019.11.002","DOI":"10.1016\/j.ccell.2019.11.002"},{"key":"5447_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11154-022-09777-y","volume":"24","author":"D Marrero-Rodriguez","year":"2023","unstructured":"Marrero-Rodriguez D, Taniguchi-Ponciano K, Kerbel J, Cano-Zaragoza A, Remba-Shapiro I, Silva-Roman G, Vela-Patino S, Andonegui-Elguera S, Valenzuela-Perez A, Mercado M (2023) The hallmarks of cancer\u2026 in pituitary tumors? Rev Endocr Metab Disord 24:177\u2013190. https:\/\/doi.org\/10.1007\/s11154-022-09777-y","journal-title":"Rev Endocr Metab Disord"},{"key":"5447_CR18","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1158\/1078-0432.CCR-16-0790","volume":"23","author":"WL Bi","year":"2017","unstructured":"Bi WL, Horowitz P, Greenwald NF, Abedalthagafi M, Agarwalla PK, Gibson WJ, Mei Y, Schumacher SE, Ben-David U, Chevalier A, Carter S, Tiao G, Brastianos PK, Ligon AH, Ducar M, MacConaill L, Laws ER Jr., Santagata S, Beroukhim R, Dunn IF (2017) Landscape of genomic alterations in pituitary adenomas. Clin Cancer Res 23:1841\u20131851. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0790","journal-title":"Clin Cancer Res"},{"key":"5447_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s40478-020-01067-5","volume":"8","author":"H Lasolle","year":"2020","unstructured":"Lasolle H, Elsensohn MH, Wierinckx A, Alix E, Bonnefille C, Vasiljevic A, Cortet C, Decoudier B, Sturm N, Gaillard S, Ferriere A, Roy P, Jouanneau E, Bertolino P, Bardel C, Sanlaville D, Raverot G (2020) Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis. Acta Neuropathol Commun 8:190. https:\/\/doi.org\/10.1186\/s40478-020-01067-5","journal-title":"Acta Neuropathol Commun"},{"key":"5447_CR20","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1038\/s41467-020-16052-8","volume":"11","author":"C Li","year":"2020","unstructured":"Li C, Xie W, Rosenblum JS, Zhou J, Guo J, Miao Y, Shen Y, Wang H, Gong L, Li M, Zhao S, Cheng S, Zhu H, Jiang T, Ling S, Wang F, Zhang H, Zhang M, Qu Y, Zhang Q, Li G, Wang J, Ma J, Zhuang Z, Zhang Y (2020) Somatic SF3B1 hotspot mutation in prolactinomas. Nat Commun 11:2506. https:\/\/doi.org\/10.1038\/s41467-020-16052-8","journal-title":"Nat Commun"},{"key":"5447_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13046-022-02245-0","volume":"41","author":"J Guo","year":"2022","unstructured":"Guo J, Li C, Fang Q, Liu Y, Wang D, Chen Y, Xie W, Zhang Y (2022) The SF3B1(R625H) mutation promotes prolactinoma tumor progression through aberrant splicing of DLG1. J Exp Clin Cancer Res 41:26. https:\/\/doi.org\/10.1186\/s13046-022-02245-0","journal-title":"J Exp Clin Cancer Res"},{"key":"5447_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fmed.2015.00054","volume":"2","author":"M Roche","year":"2015","unstructured":"Roche M, Wierinckx A, Croze S, Rey C, Legras-Lachuer C, Morel AP, Fusco A, Raverot G, Trouillas J, Lachuer J (2015) Deregulation of miR-183 and KIAA0101 in aggressive and malignant pituitary tumors. Front Med (Lausanne) 2:54. https:\/\/doi.org\/10.3389\/fmed.2015.00054","journal-title":"Front Med (Lausanne)"},{"key":"5447_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nrc2271","volume":"7","author":"A Fusco","year":"2007","unstructured":"Fusco A, Fedele M (2007) Roles of HMGA proteins in cancer. Nat Rev Cancer 7:899\u2013910. https:\/\/doi.org\/10.1038\/nrc2271","journal-title":"Nat Rev Cancer"},{"key":"5447_CR24","first-page":"2398","volume":"62","author":"P Finelli","year":"2002","unstructured":"Finelli P, Pierantoni GM, Giardino D, Losa M, Rodeschini O, Fedele M, Valtorta E, Mortini P, Croce CM, Larizza L, Fusco A (2002) The high mobility group A2 gene is amplified and overexpressed in human prolactinomas. Cancer Res 62:2398\u20132405","journal-title":"Cancer Res"},{"key":"5447_CR25","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1080\/15384101.2017.1403682","volume":"17","author":"M Fedele","year":"2018","unstructured":"Fedele M, Paciello O, De Biase D, Monaco M, Chiappetta G, Vitiello M, Barbieri A, Rea D, Luciano A, Papparella S, Arra C, Fusco A (2018) HMGA2 cooperates with either p27(kip1) deficiency or Cdk4(R24C) mutation in pituitary tumorigenesis. Cell Cycle 17:580\u2013588. https:\/\/doi.org\/10.1080\/15384101.2017.1403682","journal-title":"Cell Cycle"},{"key":"5447_CR26","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1210\/jcem.81.2.8636285","volume":"81","author":"VK LeRiche","year":"1996","unstructured":"LeRiche VK, Asa SL, Ezzat S (1996) Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J Clin Endocrinol Metab 81:656\u2013662. https:\/\/doi.org\/10.1210\/jcem.81.2.8636285","journal-title":"J Clin Endocrinol Metab"},{"key":"5447_CR27","doi-asserted-by":"publisher","first-page":"111083","DOI":"10.1016\/j.mce.2020.111083","volume":"520","author":"D Wei","year":"2021","unstructured":"Wei D, Yu Z, Cheng Y, Jiawei H, Jian G, Hua G, Guilan D (2021) Dysregulated miR-137 and its target EGFR contribute to the progression of pituitary adenomas. Mol Cell Endocrinol 520:111083. https:\/\/doi.org\/10.1016\/j.mce.2020.111083","journal-title":"Mol Cell Endocrinol"},{"key":"5447_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1677\/joe.0.1580425","volume":"158","author":"ML Jaffrain-Rea","year":"1998","unstructured":"Jaffrain-Rea ML, Petrangeli E, Lubrano C, Minniti G, Di Stefano D, Sciarra F, Frati L, Tamburrano G, Cantore G, Gulino A (1998) Epidermal growth factor binding sites in human pituitary macroadenomas. J Endocrinol 158:425\u2013433. https:\/\/doi.org\/10.1677\/joe.0.1580425","journal-title":"J Endocrinol"},{"key":"5447_CR29","doi-asserted-by":"publisher","first-page":"6377","DOI":"10.1158\/0008-5472.CAN-08-0508","volume":"68","author":"G Vlotides","year":"2008","unstructured":"Vlotides G, Siegel E, Donangelo I, Gutman S, Ren SG, Melmed S (2008) Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res 68:6377\u20136386. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0508","journal-title":"Cancer Res"},{"key":"5447_CR30","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3171\/2020.1.JNS193538","volume":"134","author":"S Cohen-Cohen","year":"2021","unstructured":"Cohen-Cohen S, Brown DA, Himes BT, Wheeler LP, Ruff MW, Major BT, Singh Ospina NM, Atkinson JLD, Meyer FB, Bancos I, Young WF, Van Gompel JJ (2021) Pituitary adenomas in the setting of multiple endocrine neoplasia type 1: a single-institution experience. J Neurosurg 134:1132\u20131138. https:\/\/doi.org\/10.3171\/2020.1.JNS193538","journal-title":"J Neurosurg"},{"key":"5447_CR31","doi-asserted-by":"publisher","first-page":"1242588","DOI":"10.3389\/fendo.2023.1242588","volume":"14","author":"L Vroonen","year":"2023","unstructured":"Vroonen L, Beckers A, Camby S, Cuny T, Beckers P, Jaffrain-Rea ML, Cogne M, Naves L, Ferriere A, Romanet P, Elenkova A, Karhu A, Brue T, Barlier A, Petrossians P, Daly AF (2023) The clinical and therapeutic profiles of prolactinomas associated with germline pathogenic variants in the Aryl hydrocarbon receptor interacting protein (AIP) gene. Front Endocrinol (Lausanne) 14:1242588. https:\/\/doi.org\/10.3389\/fendo.2023.1242588","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5447_CR32","doi-asserted-by":"publisher","first-page":"luaf124","DOI":"10.1210\/jcemcr\/luaf124","volume":"3","author":"L Green","year":"2025","unstructured":"Green L, Simpson M, Bahri A, Fong A, Manning P (2025) A pituitary Macroadenoma cosecreting prolactin and growth hormone in a patient with multiple endocrine neoplasia type 4. JCEM Case Rep 3:luaf124. https:\/\/doi.org\/10.1210\/jcemcr\/luaf124","journal-title":"JCEM Case Rep"},{"key":"5447_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11102-005-5079-0","volume":"8","author":"A Ciccarelli","year":"2005","unstructured":"Ciccarelli A, Daly AF, Beckers A (2005) The epidemiology of prolactinomas. Pituitary 8:3\u20136. https:\/\/doi.org\/10.1007\/s11102-005-5079-0","journal-title":"Pituitary"},{"key":"5447_CR34","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/neuonc\/noab102","volume":"23","author":"Y Cui","year":"2021","unstructured":"Cui Y, Li C, Jiang Z, Zhang S, Li Q, Liu X, Zhou Y, Li R, Wei L, Li L, Zhang Q, Wen L, Tang F, Zhou D (2021) Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors. Neuro Oncol 23:1859\u20131871. https:\/\/doi.org\/10.1093\/neuonc\/noab102","journal-title":"Neuro Oncol"},{"key":"5447_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jocn.2013.04.034","volume":"21","author":"W Li","year":"2014","unstructured":"Li W, Zhang Y, Zhang M, Huang G, Zhang Q (2014) Wnt4 is overexpressed in human pituitary adenomas and is associated with tumor invasion. J Clin Neurosci 21:137\u2013141. https:\/\/doi.org\/10.1016\/j.jocn.2013.04.034","journal-title":"J Clin Neurosci"},{"key":"5447_CR36","doi-asserted-by":"publisher","first-page":"9093","DOI":"10.3390\/cimb46080538","volume":"46","author":"I Balinisteanu","year":"2024","unstructured":"Balinisteanu I, Caba L, Florea A, Popescu R, Florea L, Ungureanu MC, Leustean L, Gorduza EV, Preda C (2024) Unlocking the genetic secrets of acromegaly: exploring the role of genetics in a rare disorder. Curr Issues Mol Biol 46:9093\u20139121. https:\/\/doi.org\/10.3390\/cimb46080538","journal-title":"Curr Issues Mol Biol"},{"key":"5447_CR37","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-16-0452","volume":"22","author":"F Caimari","year":"2016","unstructured":"Caimari F, Korbonits M (2016) Novel genetic causes of pituitary adenomas. Clin Cancer Res 22:5030\u20135042. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0452","journal-title":"Clin Cancer Res"},{"key":"5447_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.mce.2010.05.001","volume":"326","author":"Z Ozfirat","year":"2010","unstructured":"Ozfirat Z, Korbonits M (2010) AIP gene and Familial isolated pituitary adenomas. Mol Cell Endocrinol 326:71\u201379. https:\/\/doi.org\/10.1016\/j.mce.2010.05.001","journal-title":"Mol Cell Endocrinol"},{"key":"5447_CR39","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.ajhg.2017.03.011","volume":"100","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Peng C, Song J, Zhang Y, Chen J, Song Z, Shou X, Ma Z, Peng H, Jian X, He W, Ye Z, Li Z, Wang Y, Ye H, Zhang Z, Shen M, Tang F, Chen H, Shi Z, Chen C, Chen Z, Shen Y, Wang Y, Lu S, Zhang J, Li Y, Li S, Mao Y, Zhou L, Yan H, Shi Y, Huang C, Zhao Y (2017) Germline mutations in CDH23, encoding Cadherin-Related 23, are associated with both Familial and sporadic pituitary adenomas. Am J Hum Genet 100:817\u2013823. https:\/\/doi.org\/10.1016\/j.ajhg.2017.03.011","journal-title":"Am J Hum Genet"},{"key":"5447_CR40","doi-asserted-by":"publisher","first-page":"596554","DOI":"10.3389\/fendo.2020.596554","volume":"11","author":"M Chang","year":"2020","unstructured":"Chang M, Yang C, Bao X, Wang R (2020) Genetic and epigenetic causes of pituitary adenomas. Front Endocrinol (Lausanne) 11:596554. https:\/\/doi.org\/10.3389\/fendo.2020.596554","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5447_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40478-016-0328-1","volume":"4","author":"D Iacovazzo","year":"2016","unstructured":"Iacovazzo D, Caswell R, Bunce B, Jose S, Yuan B, Hern\u00e1ndez-Ram\u00edrez LC, Kapur S, Caimari F, Evanson J, Ferra\u00f9 F, Dang MN, Gabrovska P, Larkin SJ, Ansorge O, Rodd C, Vance ML, Ram\u00edrez-Renteria C, Mercado M, Goldstone AP, Buchfelder M, Burren CP, Gurlek A, Dutta P, Choong CS, Cheetham T, Trivellin G, Stratakis CA, Lopes MB, Grossman AB, Trouillas J, Lupski JR, Ellard S, Sampson JR, Roncaroli F, Korbonits M (2016) Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta Neuropathol Commun 4:56. https:\/\/doi.org\/10.1186\/s40478-016-0328-1","journal-title":"Acta Neuropathol Commun"},{"key":"5447_CR42","doi-asserted-by":"publisher","first-page":"M85","DOI":"10.1530\/EJE-15-0209","volume":"173","author":"R Correa","year":"2015","unstructured":"Correa R, Salpea P, Stratakis CA (2015) Carney complex: an update. Eur J Endocrinol 173:M85\u201397. https:\/\/doi.org\/10.1530\/EJE-15-0209","journal-title":"Eur J Endocrinol"},{"key":"5447_CR43","doi-asserted-by":"publisher","unstructured":"Boguslawska A, Korbonits M (2021) Genetics of acromegaly and gigantism. J Clin Med 10. https:\/\/doi.org\/10.3390\/jcm10071377","DOI":"10.3390\/jcm10071377"},{"key":"5447_CR44","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1210\/jc.2013-3826","volume":"99","author":"S Salenave","year":"2014","unstructured":"Salenave S, Boyce AM, Collins MT, Chanson P (2014) Acromegaly and McCune-Albright syndrome. J Clin Endocrinol Metab 99:1955\u20131969. https:\/\/doi.org\/10.1210\/jc.2013-3826","journal-title":"J Clin Endocrinol Metab"},{"key":"5447_CR45","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1056\/NEJM199112123252403","volume":"325","author":"LS Weinstein","year":"1991","unstructured":"Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM (1991) Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688\u20131695. https:\/\/doi.org\/10.1056\/NEJM199112123252403","journal-title":"N Engl J Med"},{"key":"5447_CR46","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3803\/EnM.2020.875","volume":"36","author":"H Jung","year":"2021","unstructured":"Jung H, Kim K, Kim D, Moon JH, Kim EH, Kim SH, Ku CR, Lee EJ (2021) Associations of GNAS mutations with surgical outcomes in patients with growth Hormone-Secreting pituitary adenoma. Endocrinol Metab (Seoul) 36:342\u2013350. https:\/\/doi.org\/10.3803\/EnM.2020.875","journal-title":"Endocrinol Metab (Seoul)"},{"key":"5447_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1530\/EJE-12-0457","volume":"168","author":"J Oriola","year":"2013","unstructured":"Oriola J, Lucas T, Halperin I, Mora M, Perales MJ, Alvarez-Escola C, Paz de MN, Diaz Soto G, Salinas I, Julian MT, Olaizola I, Bernabeu I, Marazuela M, Puig-Domingo M (2013) Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. Eur J Endocrinol 168:9\u201313. https:\/\/doi.org\/10.1530\/EJE-12-0457","journal-title":"Eur J Endocrinol"},{"key":"5447_CR48","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1530\/ERC-15-0320","volume":"22","author":"L Rostomyan","year":"2015","unstructured":"Rostomyan L, Daly AF, Petrossians P, Nachev E, Lila AR, Lecoq AL, Lecumberri B, Trivellin G, Salvatori R, Moraitis AG, Holdaway I, Kranenburg-van Klaveren DJ, Chiara Zatelli M, Palacios N, Nozieres C, Zacharin M, Ebeling T, Ojaniemi M, Rozhinskaya L, Verrua E, Jaffrain-Rea ML, Filipponi S, Gusakova D, Pronin V, Bertherat J, Belaya Z, Ilovayskaya I, Sahnoun-Fathallah M, Sievers C, Stalla GK, Castermans E, Caberg JH, Sorkina E, Auriemma RS, Mittal S, Kareva M, Lysy PA, Emy P, De Menis E, Choong CS, Mantovani G, Bours V, De Herder W, Brue T, Barlier A, Neggers SJ, Zacharieva S, Chanson P, Shah NS, Stratakis CA, Naves LA, Beckers A (2015) Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer 22:745\u2013757. https:\/\/doi.org\/10.1530\/ERC-15-0320","journal-title":"Endocr Relat Cancer"},{"key":"5447_CR49","unstructured":"Persani L, Lania A, Beck-Peccoz P (2000) Thyrotropin-secreting pituitary adenomas. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP (eds) Endotext. South Dartmouth (MA)"},{"key":"5447_CR50","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1210\/jcem.86.11.7984","volume":"86","author":"S Ando","year":"2001","unstructured":"Ando S, Sarlis NJ, Oldfield EH, Yen PM (2001) Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab 86:5572\u20135576. https:\/\/doi.org\/10.1210\/jcem.86.11.7984","journal-title":"J Clin Endocrinol Metab"},{"key":"5447_CR51","doi-asserted-by":"publisher","first-page":"E948","DOI":"10.1210\/jc.2010-2496","volume":"96","author":"T Tagami","year":"2011","unstructured":"Tagami T, Usui T, Shimatsu A, Beniko M, Yamamoto H, Moriyama K, Naruse M (2011) Aberrant expression of thyroid hormone receptor beta isoform May cause inappropriate secretion of TSH in a TSH-secreting pituitary adenoma. J Clin Endocrinol Metab 96:E948\u2013952. https:\/\/doi.org\/10.1210\/jc.2010-2496","journal-title":"J Clin Endocrinol Metab"},{"key":"5447_CR52","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1210\/jc.2014-3994","volume":"100","author":"X Teng","year":"2015","unstructured":"Teng X, Jin T, Brent GA, Wu A, Teng W, Shan Z (2015) A patient with a Thyrotropin-Secreting microadenoma and resistance to thyroid hormone (P453T). J Clin Endocrinol Metab 100:2511\u20132514. https:\/\/doi.org\/10.1210\/jc.2014-3994","journal-title":"J Clin Endocrinol Metab"},{"key":"5447_CR53","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1210\/mend.15.9.0687","volume":"15","author":"S Ando","year":"2001","unstructured":"Ando S, Sarlis NJ, Krishnan J, Feng X, Refetoff S, Zhang MQ, Oldfield EH, Yen PM (2001) Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance. Mol Endocrinol 15:1529\u20131538. https:\/\/doi.org\/10.1210\/mend.15.9.0687","journal-title":"Mol Endocrinol"},{"key":"5447_CR54","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1128\/MCB.25.1.124-135.2005","volume":"25","author":"H Furumoto","year":"2005","unstructured":"Furumoto H, Ying H, Chandramouli GV, Zhao L, Walker RL, Meltzer PS, Willingham MC, Cheng SY (2005) An unliganded thyroid hormone beta receptor activates the Cyclin D1\/cyclin-dependent kinase\/retinoblastoma\/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol 25:124\u2013135. https:\/\/doi.org\/10.1128\/MCB.25.1.124-135.2005","journal-title":"Mol Cell Biol"},{"key":"5447_CR55","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1046\/j.1365-2265.2002.01541.x","volume":"56","author":"LA Tannahill","year":"2002","unstructured":"Tannahill LA, Visser TJ, McCabe CJ, Kachilele S, Boelaert K, Sheppard MC, Franklyn JA, Gittoes NJ (2002) Dysregulation of Iodothyronine deiodinase enzyme expression and function in human pituitary tumours. Clin Endocrinol (Oxf) 56:735\u2013743. https:\/\/doi.org\/10.1046\/j.1365-2265.2002.01541.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"5447_CR56","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1210\/me.2005-0378","volume":"20","author":"MA Charles","year":"2006","unstructured":"Charles MA, Saunders TL, Wood WM, Owens K, Parlow AF, Camper SA, Ridgway EC, Gordon DF (2006) Pituitary-specific Gata2 knockout: effects on gonadotrope and thyrotrope function. Mol Endocrinol 20:1366\u20131377. https:\/\/doi.org\/10.1210\/me.2005-0378","journal-title":"Mol Endocrinol"},{"key":"5447_CR57","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/modpathol.3880484","volume":"15","author":"K Umeoka","year":"2002","unstructured":"Umeoka K, Sanno N, Osamura RY, Teramoto A (2002) Expression of GATA-2 in human pituitary adenomas. Mod Pathol 15:11\u201317. https:\/\/doi.org\/10.1038\/modpathol.3880484","journal-title":"Mod Pathol"},{"key":"5447_CR58","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1677\/JME-08-0099","volume":"42","author":"Y Kashiwabara","year":"2009","unstructured":"Kashiwabara Y, Sasaki S, Matsushita A, Nagayama K, Ohba K, Iwaki H, Matsunaga H, Suzuki S, Misawa H, Ishizuka K, Oki Y, Nakamura H (2009) Functions of PIT1 in GATA2-dependent transactivation of the Thyrotropin beta promoter. J Mol Endocrinol 42:225\u2013237. https:\/\/doi.org\/10.1677\/JME-08-0099","journal-title":"J Mol Endocrinol"},{"key":"5447_CR59","doi-asserted-by":"publisher","first-page":"e18667","DOI":"10.1371\/journal.pone.0018667","volume":"6","author":"K Ohba","year":"2011","unstructured":"Ohba K, Sasaki S, Matsushita A, Iwaki H, Matsunaga H, Suzuki S, Ishizuka K, Misawa H, Oki Y, Nakamura H (2011) GATA2 mediates Thyrotropin-releasing hormone-induced transcriptional activation of the Thyrotropin beta gene. PLoS ONE 6:e18667. https:\/\/doi.org\/10.1371\/journal.pone.0018667","journal-title":"PLoS ONE"},{"key":"5447_CR60","doi-asserted-by":"publisher","first-page":"e0142400","DOI":"10.1371\/journal.pone.0142400","volume":"10","author":"H Matsunaga","year":"2015","unstructured":"Matsunaga H, Sasaki S, Suzuki S, Matsushita A, Nakamura H, Nakamura HM, Hirahara N, Kuroda G, Iwaki H, Ohba K, Morita H, Oki Y, Suda T (2015) Essential role of GATA2 in the negative regulation of type 2 deiodinase gene by liganded thyroid hormone receptor beta2 in thyrotroph. PLoS ONE 10:e0142400. https:\/\/doi.org\/10.1371\/journal.pone.0142400","journal-title":"PLoS ONE"},{"key":"5447_CR61","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/neuonc\/noz109","volume":"21","author":"S Sbiera","year":"2019","unstructured":"Sbiera S, Perez-Rivas LG, Taranets L, Weigand I, Flitsch J, Graf E, Monoranu CM, Saeger W, Hagel C, Honegger J, Assie G, Hermus AR, Stalla GK, Herterich S, Ronchi CL, Deutschbein T, Reincke M, Strom TM, Popov N, Theodoropoulou M, Fassnacht M (2019) Driver mutations in USP8 wild-type cushing\u2019s disease. Neuro Oncol 21:1273\u20131283. https:\/\/doi.org\/10.1093\/neuonc\/noz109","journal-title":"Neuro Oncol"},{"key":"5447_CR62","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1096\/fj.04-2138fje","volume":"19","author":"G Vila","year":"2005","unstructured":"Vila G, Papazoglou M, Stalla J, Theodoropoulou M, Stalla GK, Holsboer F, Paez-Pereda M (2005) Sonic Hedgehog regulates CRH signal transduction in the adult pituitary. FASEB J 19:281\u2013283. https:\/\/doi.org\/10.1096\/fj.04-2138fje","journal-title":"FASEB J"},{"key":"5447_CR63","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ng.3166","volume":"47","author":"M Reincke","year":"2015","unstructured":"Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, Meitinger T, Mizuno-Yamasaki E, Kawaguchi K, Saeki Y, Tanaka K, Wieland T, Graf E, Saeger W, Ronchi CL, Allolio B, Buchfelder M, Strom TM, Fassnacht M, Komada M (2015) Mutations in the deubiquitinase gene USP8 cause cushing\u2019s disease. Nat Genet 47:31\u201338. https:\/\/doi.org\/10.1038\/ng.3166","journal-title":"Nat Genet"},{"key":"5447_CR64","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1677\/joe.1.05616","volume":"183","author":"M Theodoropoulou","year":"2004","unstructured":"Theodoropoulou M, Arzberger T, Gruebler Y, Jaffrain-Rea ML, Schlegel J, Schaaf L, Petrangeli E, Losa M, Stalla GK, Pagotto U (2004) Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol 183:385\u2013394. https:\/\/doi.org\/10.1677\/joe.1.05616","journal-title":"J Endocrinol"},{"key":"5447_CR65","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3389\/fendo.2019.00785","volume":"10","author":"X Liu","year":"2019","unstructured":"Liu X, Feng M, Dai C, Bao X, Deng K, Yao Y, Wang R (2019) Expression of EGFR in pituitary corticotroph adenomas and its relationship with tumor behavior. Front Endocrinol (Lausanne) 10:785. https:\/\/doi.org\/10.3389\/fendo.2019.00785","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5447_CR66","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1210\/js.2016-1053","volume":"1","author":"T Araki","year":"2017","unstructured":"Araki T, Liu X, Kameda H, Tone Y, Fukuoka H, Tone M, Melmed S (2017) EGFR induces E2F1-Mediated corticotroph tumorigenesis. J Endocr Soc 1:127\u2013143. https:\/\/doi.org\/10.1210\/js.2016-1053","journal-title":"J Endocr Soc"},{"key":"5447_CR67","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1507\/endocrj.EJ18-0491","volume":"66","author":"Y Asari","year":"2019","unstructured":"Asari Y, Kageyama K, Sugiyama A, Kogawa H, Niioka K, Daimon M (2019) Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells. Endocr J 66:515\u2013522. https:\/\/doi.org\/10.1507\/endocrj.EJ18-0491","journal-title":"Endocr J"},{"key":"5447_CR68","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1172\/JCI60417","volume":"121","author":"H Fukuoka","year":"2011","unstructured":"Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, Melmed S (2011) EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 121:4712\u20134721. https:\/\/doi.org\/10.1172\/JCI60417","journal-title":"J Clin Invest"},{"key":"5447_CR69","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1038\/s41467-018-05275-5","volume":"9","author":"J Chen","year":"2018","unstructured":"Chen J, Jian X, Deng S, Ma Z, Shou X, Shen Y, Zhang Q, Song Z, Li Z, Peng H, Peng C, Chen M, Luo C, Zhao D, Ye Z, Shen M, Zhang Y, Zhou J, Fahira A, Wang Y, Li S, Zhang Z, Ye H, Li Y, Shen J, Chen H, Tang F, Yao Z, Shi Z, Chen C, Xie L, Wang Y, Fu C, Mao Y, Zhou L, Gao D, Yan H, Zhao Y, Huang C, Shi Y (2018) Identification of recurrent USP48 and BRAF mutations in cushing\u2019s disease. Nat Commun 9:3171. https:\/\/doi.org\/10.1038\/s41467-018-05275-5","journal-title":"Nat Commun"},{"key":"5447_CR70","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1016\/j.gim.2022.08.021","volume":"24","author":"LC Hern\u00e1ndez-Ram\u00edrez","year":"2022","unstructured":"Hern\u00e1ndez-Ram\u00edrez LC, Pankratz N, Lane J, Faucz FR, Chittiboina P, Kay DM, Beethem Z, Mills JL, Stratakis CA (2022) Genetic drivers of cushing\u2019s disease: frequency and associated phenotypes. Genet Sci 24:2516\u20132525. https:\/\/doi.org\/10.1016\/j.gim.2022.08.021","journal-title":"Genet Sci"},{"key":"5447_CR71","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3390\/cancers11111761","volume":"11","author":"S Sbiera","year":"2019","unstructured":"Sbiera S, Kunz M, Weigand I, Deutschbein T, Dandekar T, Fassnacht M (2019) The new genetic landscape of cushing\u2019s disease: deubiquitinases in the spotlight. Cancers 11:1761","journal-title":"Cancers"},{"key":"5447_CR72","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1530\/EJE-07-0428","volume":"157","author":"T Tateno","year":"2007","unstructured":"Tateno T, Izumiyama H, Doi M, Yoshimoto T, Shichiri M, Inoshita N, Oyama K, Yamada S, Hirata Y (2007) Differential gene expression in ACTH -secreting and non-functioning pituitary tumors. Eur J Endocrinol 157:717\u2013724. https:\/\/doi.org\/10.1530\/EJE-07-0428","journal-title":"Eur J Endocrinol"},{"key":"5447_CR73","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1210\/jc.2018-00688","volume":"104","author":"J Drummond","year":"2019","unstructured":"Drummond J, Roncaroli F, Grossman AB, Korbonits M (2019) Clinical and pathological aspects of silent pituitary adenomas. J Clin Endocrinol Metab 104:2473\u20132489. https:\/\/doi.org\/10.1210\/jc.2018-00688","journal-title":"J Clin Endocrinol Metab"},{"key":"5447_CR74","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1530\/ERC-18-0330","volume":"26","author":"P Xekouki","year":"2019","unstructured":"Xekouki P, Lodge EJ, Matschke J, Santambrogio A, Apps JR, Sharif A, Jacques TS, Aylwin S, Prevot V, Li R, Flitsch J, Bornstein SR, Theodoropoulou M, Andoniadou CL (2019) Non-secreting pituitary tumours characterised by enhanced expression of YAP\/TAZ. Endocr Relat Cancer 26:215\u2013225. https:\/\/doi.org\/10.1530\/ERC-18-0330","journal-title":"Endocr Relat Cancer"},{"key":"5447_CR75","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41392-022-01191-9","volume":"7","author":"M Fu","year":"2022","unstructured":"Fu M, Hu Y, Lan T, Guan KL, Luo T, Luo M (2022) The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther 7:376. https:\/\/doi.org\/10.1038\/s41392-022-01191-9","journal-title":"Signal Transduct Target Ther"},{"key":"5447_CR76","doi-asserted-by":"publisher","unstructured":"Lodge EJ, Santambrogio A, Russell JP, Xekouki P, Jacques TS, Johnson RL, Thavaraj S, Bornstein SR, Andoniadou CL (2019) Homeostatic and tumourigenic activity of SOX2+\u2009pituitary stem cells is controlled by the LATS\/YAP\/TAZ cascade. Elife 8. https:\/\/doi.org\/10.7554\/eLife.43996","DOI":"10.7554\/eLife.43996"},{"key":"5447_CR77","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1210\/en.2016-1967","volume":"158","author":"WL Bi","year":"2017","unstructured":"Bi WL, Greenwald NF, Ramkissoon SH, Abedalthagafi M, Coy SM, Ligon KL, Mei Y, MacConaill L, Ducar M, Min L, Santagata S, Kaiser UB, Beroukhim R, Laws ER Jr., Dunn IF (2017) Clinical identification of oncogenic drivers and Copy-Number alterations in pituitary tumors. Endocrinology 158:2284\u20132291. https:\/\/doi.org\/10.1210\/en.2016-1967","journal-title":"Endocrinology"},{"key":"5447_CR78","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","volume":"17","author":"G Raverot","year":"2021","unstructured":"Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, Brue T (2021) Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol 17:671\u2013684. https:\/\/doi.org\/10.1038\/s41574-021-00550-w","journal-title":"Nat Rev Endocrinol"},{"key":"5447_CR79","doi-asserted-by":"publisher","unstructured":"De Sousa SMC, Lenders NF, Lamb LS, Inder WJ, McCormack A (2023) Pituitary tumours: molecular and genetic aspects. J Endocrinol 257. https:\/\/doi.org\/10.1530\/JOE-22-0291","DOI":"10.1530\/JOE-22-0291"},{"key":"5447_CR80","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.anndiagpath.2019.04.016","volume":"41","author":"G Trott","year":"2019","unstructured":"Trott G, Ongaratti BR, de Oliveira Silva CB, Abech GD, Haag T, Rech C, Ferreira NP, da Costa Oliveira M, Pereira-Lima JFS (2019) PTTG overexpression in non-functioning pituitary adenomas: correlation with invasiveness, female gender and younger age. Ann Diagn Pathol 41:83\u201389. https:\/\/doi.org\/10.1016\/j.anndiagpath.2019.04.016","journal-title":"Ann Diagn Pathol"},{"key":"5447_CR81","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s40478-022-01437-1","volume":"10","author":"LG Perez-Rivas","year":"2022","unstructured":"Perez-Rivas LG, Simon J, Albani A, Tang S, Roeber S, Assie G, Deutschbein T, Fassnacht M, Gadelha MR, Hermus AR, Stalla GK, Tichomirowa MA, Rotermund R, Flitsch J, Buchfelder M, Nasi-Kordhishti I, Honegger J, Thorsteinsdottir J, Saeger W, Herms J, Reincke M, Theodoropoulou M (2022) TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome. Acta Neuropathol Commun 10:139. https:\/\/doi.org\/10.1186\/s40478-022-01437-1","journal-title":"Acta Neuropathol Commun"},{"key":"5447_CR82","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.humpath.2017.03.028","volume":"66","author":"B Liu","year":"2017","unstructured":"Liu B, Pang B, Wang Q, Yang S, Gao T, Ding Q, Liu H, Yang Y, Fan H, Zhang R, Xin T, Xu G, Pang Q (2017) EZH2 upregulation correlates with tumor invasiveness, proliferation, and angiogenesis in human pituitary adenomas. Hum Pathol 66:101\u2013107. https:\/\/doi.org\/10.1016\/j.humpath.2017.03.028","journal-title":"Hum Pathol"},{"key":"5447_CR83","doi-asserted-by":"publisher","unstructured":"Serioli S, Agostini L, Pietrantoni A, Valeri F, Costanza F, Chiloiro S, Buffoli B, Piazza A, Poliani PL, Peris-Celda M, Iavarone F, Gaudino S, Gessi M, Schinzari G, Mattogno PP, Giampietro A, De Marinis L, Pontecorvi A, Fontanella MM, Lauretti L, Rindi G, Olivi A, Bianchi A, Doglietto F (2023) Aggressive PitNETs and potential target therapies: a systematic review of molecular and genetic pathways. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms242115719","DOI":"10.3390\/ijms242115719"},{"key":"5447_CR84","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1016\/j.humpath.2013.05.020","volume":"44","author":"A Righi","year":"2013","unstructured":"Righi A, Morandi L, Leonardi E, Farnedi A, Marucci G, Sisto A, Frank G, Faustini-Fustini M, Zoli M, Mazzatenta D, Agati R, Foschini MP (2013) Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior. Hum Pathol 44:2400\u20132409. https:\/\/doi.org\/10.1016\/j.humpath.2013.05.020","journal-title":"Hum Pathol"},{"key":"5447_CR85","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/ijc.30173","volume":"139","author":"J Wang","year":"2016","unstructured":"Wang J, Voellger B, Benzel J, Schlomann U, Nimsky C, Bartsch JW, Carl B (2016) Metalloproteinases ADAM12 and MMP-14 are associated with cavernous sinus invasion in pituitary adenomas. Int J Cancer 139:1327\u20131339. https:\/\/doi.org\/10.1002\/ijc.30173","journal-title":"Int J Cancer"},{"key":"5447_CR86","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/modpathol.2008.202","volume":"22","author":"ZR Qian","year":"2009","unstructured":"Qian ZR, Asa SL, Siomi H, Siomi MC, Yoshimoto K, Yamada S, Wang EL, Rahman MM, Inoue H, Itakura M, Kudo E, Sano T (2009) Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod Pathol 22:431\u2013441. https:\/\/doi.org\/10.1038\/modpathol.2008.202","journal-title":"Mod Pathol"},{"key":"5447_CR87","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noae148","volume":"27","author":"S Chaudhary","year":"2025","unstructured":"Chaudhary S, Das U, Jabbar S, Gangisetty O, Rousseau B, Hanft S, Sarkar DK (2025) Developmental pluripotency-associated 4 increases aggressiveness of pituitary neuroendocrine tumors by enhancing cell stemness. Neuro Oncol 27:123\u2013139. https:\/\/doi.org\/10.1093\/neuonc\/noae148","journal-title":"Neuro Oncol"},{"key":"5447_CR88","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1210\/clinem\/dgaa749","volume":"106","author":"O Casar-Borota","year":"2021","unstructured":"Casar-Borota O, Boldt HB, Engstrom BE, Andersen MS, Baussart B, Bengtsson D, Berinder K, Ekman B, Feldt-Rasmussen U, Hoybye C, Jorgensen JOL, Kolnes AJ, Korbonits M, Rasmussen AK, Lindsay JR, Loughrey PB, Maiter D, Manojlovic-Gacic E, Pahnke J, Poliani PL, Popovic V, Ragnarsson O, Schalin-Jantti C, Scheie D, Toth M, Villa C, Wirenfeldt M, Kunicki J, Burman P (2021) Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations. J Clin Endocrinol Metab 106:1183\u20131194. https:\/\/doi.org\/10.1210\/clinem\/dgaa749","journal-title":"J Clin Endocrinol Metab"},{"key":"5447_CR89","doi-asserted-by":"publisher","unstructured":"Cossu G, La Rosa S, Brouland JP, Pitteloud N, Harel E, Santoni F, Brunner M, Daniel RT, Messerer M (2023) PD-L1 expression in pituitary neuroendocrine tumors\/pituitary adenomas. Cancers (Basel) 15. https:\/\/doi.org\/10.3390\/cancers15184471","DOI":"10.3390\/cancers15184471"},{"key":"5447_CR90","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1385\/ENDO:28:1:115","volume":"28","author":"MB Lopes","year":"2005","unstructured":"Lopes MB, Scheithauer BW, Schiff D (2005) Pituitary carcinoma: diagnosis and treatment. Endocrine 28:115\u2013121. https:\/\/doi.org\/10.1385\/ENDO:28:1:115","journal-title":"Endocrine"},{"key":"5447_CR91","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11154-020-09562-9","volume":"21","author":"J Trouillas","year":"2020","unstructured":"Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Dekkers O, Popovic V, Wierinckx A, McCormack A, Petersenn S, Burman P, Raverot G, Villa C (2020) Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician\u2019s questions. Rev Endocr Metab Disord 21:243\u2013251. https:\/\/doi.org\/10.1007\/s11154-020-09562-9","journal-title":"Rev Endocr Metab Disord"},{"key":"5447_CR92","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12020-013-0093-x","volume":"46","author":"O Cooper","year":"2014","unstructured":"Cooper O, Mamelak A, Bannykh S, Carmichael J, Bonert V, Lim S, Cook-Wiens G, Ben-Shlomo A (2014) Prolactinoma erbb receptor expression and targeted therapy for aggressive tumors. Endocrine 46:318\u2013327. https:\/\/doi.org\/10.1007\/s12020-013-0093-x","journal-title":"Endocrine"},{"key":"5447_CR93","doi-asserted-by":"publisher","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","volume":"106","author":"O Cooper","year":"2021","unstructured":"Cooper O, Bonert VS, Rudnick J, Pressman BD, Lo J, Salvatori R, Yuen KCJ, Fleseriu M, Melmed S (2021) EGFR\/ErbB2-Targeting lapatinib therapy for aggressive prolactinomas. J Clin Endocrinol Metab 106:e917\u2013e925. https:\/\/doi.org\/10.1210\/clinem\/dgaa805","journal-title":"J Clin Endocrinol Metab"},{"key":"5447_CR94","unstructured":"Zhang Z (2015) Targeted therapy with gefitinib in patients with USP8-mutated Cushing\u2019s disease. https:\/\/clinicaltrials.gov\/study\/NCT02484755. Accessed 28 Jun 2025"},{"key":"5447_CR95","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1210\/clinem\/dgac588","volume":"108","author":"NA Liu","year":"2023","unstructured":"Liu NA, Ben-Shlomo A, Carmichael JD, Wang C, Swerdloff RS, Heaney AP, Barkhoudarian G, Kelly D, Noureddin M, Lu L, Desai M, Stolyarov Y, Yuen K, Mamelak AN, Mirocha J, Tighiouart M, Melmed S (2023) Treatment of Cushing disease with Pituitary-Targeting Seliciclib. J Clin Endocrinol Metab 108:726\u2013735. https:\/\/doi.org\/10.1210\/clinem\/dgac588","journal-title":"J Clin Endocrinol Metab"},{"key":"5447_CR96","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1227\/neu.0000000000002024","volume":"91","author":"S Shah","year":"2022","unstructured":"Shah S, Manzoor S, Rothman Y, Hagen M, Pater L, Golnik K, Mahammedi A, Lin AL, Bhabhra R, Forbes JA, Sengupta S (2022) Complete response of a patient with a mismatch repair deficient aggressive pituitary adenoma to immune checkpoint inhibitor therapy: A case report. Neurosurgery 91:e51\u2013e56. https:\/\/doi.org\/10.1227\/neu.0000000000002024","journal-title":"Neurosurgery"},{"key":"5447_CR97","doi-asserted-by":"publisher","first-page":"C7","DOI":"10.1530\/EJE-18-0250","volume":"178","author":"J Trouillas","year":"2018","unstructured":"Trouillas J, Burman P, McCormack A, Petersenn S, Popovic V, Dekkers O, Raverot G (2018) Aggressive pituitary tumours and carcinomas: two sides of the same coin? Eur J Endocrinol 178:C7\u2013C9. https:\/\/doi.org\/10.1530\/EJE-18-0250","journal-title":"Eur J Endocrinol"},{"key":"5447_CR98","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","volume":"286","author":"HA Schmid","year":"2008","unstructured":"Schmid HA (2008) Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 286:69\u201374. https:\/\/doi.org\/10.1016\/j.mce.2007.09.006","journal-title":"Mol Cell Endocrinol"},{"key":"5447_CR99","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1210\/jc.2009-2272","volume":"95","author":"S Petersenn","year":"2010","unstructured":"Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM, Pasireotide Acromegaly Study G (2010) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 95:2781\u20132789. https:\/\/doi.org\/10.1210\/jc.2009-2272","journal-title":"J Clin Endocrinol Metab"},{"key":"5447_CR100","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","volume":"6","author":"A Lacroix","year":"2018","unstructured":"Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, Boscaro M, Salvatori R, Yamada M, Tauchmanova L, Roughton M, Ravichandran S, Petersenn S, Biller BMK, Newell-Price J, Pasireotide GSG (2018) Efficacy and safety of once-monthly Pasireotide in cushing\u2019s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol 6:17\u201326. https:\/\/doi.org\/10.1016\/S2213-8587(17)30326-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5447_CR101","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae163.1201","author":"BM Biller","year":"2024","unstructured":"Biller BM, Casagrande A, Elenkova A, Boguszewski CL, Jallad RS, Hu B, Hubina E, Fazeli P, Fleseriu M, Snyder PJ, Strasburger CJ, Bidlingmaier M, Buchfelder M, Trainer PJ, Struthers S, Krasner A, Gadelha M (2024) 12535 efficacy and safety of Once-daily oral Paltusotine in medically untreated patients with acromegaly: results from the phase 3, Randomized, Placebo-controlled Pathfndr-2 study. J Endocr Soc 8. https:\/\/doi.org\/10.1210\/jendso\/bvae163.1201","journal-title":"J Endocr Soc 8"},{"key":"5447_CR102","doi-asserted-by":"publisher","first-page":"100923","DOI":"10.1016\/j.lanepe.2024.100923","volume":"42","author":"TM Boertien","year":"2024","unstructured":"Boertien TM, Drent ML, Booij J, Majoie C, Stokkel MPM, Hoogmoed J, Pereira AM, Biermasz NR, Simsek S, Veldman RG, Weterings AJ, Vink JM, Tanck MWT, Fliers E, Bisschop PH (2024) Lanreotide versus placebo for tumour reduction in patients with a (68)Ga-DOTATATE PET-positive, clinically non-functioning pituitary Macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment. Lancet Reg Health Eur 42:100923. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100923","journal-title":"Lancet Reg Health Eur"},{"key":"5447_CR103","unstructured":"Ionis Pharmaceuticals Inc (2022) Safety, tolerability, and efficacy of IONIS-GHR-LRx in participants with acromegaly being treated with long-acting somatostatin receptor ligands. https:\/\/clinicaltrials.gov\/study\/NCT03548415. Accessed 26 July 2025"},{"key":"5447_CR104","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11154-025-09944-x","volume":"26","author":"KKY Ho","year":"2025","unstructured":"Ho KKY, Melmed S (2025) Pituitary adenomas: biology, nomenclature and clinical classification. Rev Endocr Metab Disord 26:137\u2013146. https:\/\/doi.org\/10.1007\/s11154-025-09944-x","journal-title":"Rev Endocr Metab Disord"},{"key":"5447_CR105","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41574-023-00883-8","volume":"19","author":"KKY Ho","year":"2023","unstructured":"Ho KKY, Kaiser UB, Chanson P, Gadelha M, Wass J, Nieman L, Little A, Aghi MK, Raetzman L, Post K, Raverot G, Borowsky AD, Erickson D, Casta\u00f1o JP, Laws ER, Zatelli MC, Sisco J, Esserman L, Yuen KCJ, Reincke M, Melmed S (2023) Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification. Nat Reviews Endocrinol 19:671\u2013678. https:\/\/doi.org\/10.1038\/s41574-023-00883-8","journal-title":"Nat Reviews Endocrinol"},{"key":"5447_CR106","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S2213-8587(23)00382-0","volume":"12","author":"KKY Ho","year":"2024","unstructured":"Ho KKY, Fleseriu M, Wass J, Katznelson L, Raverot G, Little AS, Casta\u00f1o JP, Reincke M, Lopes MB, Kaiser UB, Chanson P, Gadelha M, Melmed S (2024) A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis. Lancet Diabetes Endocrinol 12:209\u2013214. https:\/\/doi.org\/10.1016\/S2213-8587(23)00382-0","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05447-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05447-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05447-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:05:45Z","timestamp":1781651145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05447-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["5447"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05447-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}